Q3 EPS Forecast for Trevi Therapeutics Lowered by Analyst

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for Trevi Therapeutics in a report issued on Wednesday, March 19th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.09). HC Wainwright has a "Buy" rating and a $12.50 price target on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics' Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at ($0.31) EPS.

A number of other equities research analysts have also issued reports on the company. Oppenheimer upped their target price on Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their price objective for the company from $9.00 to $29.00 in a research report on Monday, March 10th. D. Boral Capital reaffirmed a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. B. Riley reissued a "buy" rating and issued a $20.00 target price (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, Needham & Company LLC decreased their price target on shares of Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research note on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $17.56.

Remove Ads

Trevi Therapeutics Price Performance

TRVI traded up $0.21 during midday trading on Friday, reaching $6.61. 1,053,002 shares of the company's stock were exchanged, compared to its average volume of 997,669. The business's 50-day moving average price is $4.70 and its 200 day moving average price is $3.81. The stock has a market capitalization of $639.07 million, a PE ratio of -15.02 and a beta of 0.90. Trevi Therapeutics has a 1-year low of $2.30 and a 1-year high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01.

Hedge Funds Weigh In On Trevi Therapeutics

Large investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. increased its position in Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after purchasing an additional 3,283,684 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Trevi Therapeutics during the fourth quarter worth approximately $17,099,000. Vivo Capital LLC increased its position in shares of Trevi Therapeutics by 116.3% in the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company's stock worth $14,370,000 after acquiring an additional 1,875,000 shares in the last quarter. Woodline Partners LP raised its stake in shares of Trevi Therapeutics by 429.9% in the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock valued at $13,236,000 after acquiring an additional 2,606,370 shares during the period. Finally, MPM Bioimpact LLC lifted its holdings in shares of Trevi Therapeutics by 101.2% during the 4th quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company's stock valued at $12,751,000 after acquiring an additional 1,556,379 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the transaction, the insider now owns 76,900 shares in the company, valued at $519,075. This trade represents a 51.39 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jennifer L. Good sold 5,263 shares of the company's stock in a transaction on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $1,403,599.54. The trade was a 2.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.37% of the stock is owned by corporate insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.